Quintiles, London Genetics ally to enhance drug discovery and development through pharmacogenetics

Alliance combines world-class expertise and global infrastructure to support biopharma in the development of personalized medicine

02-Dec-2010 - USA

Quintiles and London Genetics announced a strategic alliance to offer the biopharmaceutical industry pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

Under the non-exclusive alliance, Quintiles and London Genetics will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, Quintiles and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.

“Our expertise in pharmacogenetic strategy development combined with Quintiles’ expertise and infrastructure in biomarker development gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development,” said Dominique Kleyn, CEO of London Genetics. “Ultimately, our alliance will support biopharma in their interactions with academic partners and the development of personalized medicine.”

Quintiles develops proprietary and novel biomarker tests analyzing genes and proteins that affect cell growth and mutation, and performs these assays at labs in the United States, Scotland and China. Quintiles has the largest central laboratory network in the world, with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, and a tightly controlled network of affiliate laboratories in Argentina and Brazil. London Genetics works with London-based centres of excellence in genetics research to provide pharmacogenetic solutions to the biopharmaceutical industry. It can help companies to partner with relevant academics and clinicians, to apply genetic knowledge to derisk clinical trials, to design and manage projects and to access patient cohorts.

https://www.bionity.com/en/news/126831/quintiles-london-genetics-ally-to-enhance-drug-discovery-and-development-through-pharmacogenetics.html